文献速递胸部肿瘤放疗

组织学确诊的I期非小细胞肺癌影像引导质子治疗的临床结局

Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer.
PubMed 文献 · Radiat Oncol · 2018-10-11

两项前瞻性II期试验评估影像引导质子治疗(IGPT)对医学上不可手术或可手术的I期非小细胞肺癌的疗效与安全性,本研究报告其中期结果。55例患者接受IGPT,中位随访35个月,3年总生存率87%、无进展生存率74%、局部控制率96%,无3级及以上急性或晚期毒性。

要点

  • 55例组织学确诊I期NSCLC接受IGPT,3年总生存率87%、局部控制率96%。
  • 2级毒性为放射性肺炎5例(9%)、肋骨骨折2例(4%)、胸壁疼痛5例(9%)。
  • 无3级或以上急性或晚期毒性。

核心结论

  • IGPT对I期非小细胞肺癌所有患者似乎有效且耐受良好。

研究设计与样本

  • 两项前瞻性II期试验(Lung-001和Lung-002)的中期结果报告,分析2013年7月至2017年2月接受IGPT的55例组织学确诊I期NSCLC患者,其中IA期33例、IB期22例,不可手术21例、可手术34例,中位年龄71岁(范围48-88岁)。

主要发现

  • 全部患者3年总生存率为87%(95%CI 73-94%),3年无进展生存率为74%(95%CI 58-85%),3年局部控制率为96%(95%CI 83-99%)。
  • 39例(71%)使用了基准金属标记匹配。
  • 2级毒性包括放射性肺炎5例(9%)、肋骨骨折2例(4%)、胸壁疼痛5例(9%)。
  • 未观察到3级或以上急性或晚期毒性。
  • 幸存者中位随访35个月(范围12-54个月)。

关键数值与推荐

  • 周边型肿瘤采用66 Gy(RBE)分10次照射(n=49),中心型肿瘤采用72.6 Gy(RBE)分22次照射(n=6)。
  • 所有治疗均使用呼吸门控方法进行运动管理。
  • 毒性评估采用不良事件通用术语标准(v.4.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two prospective phase II trials were designed to assess the efficacy and safety of image-guided proton therapy (IGPT) for either medically inoperable or operable stage I non-small cell lung cancer (NSCLC). The present study reports the interim results of these trials. METHODS: Fifty-five patients with histologically confirmed stage I NSCLC (IA in 33 patients and IB in 22 patients; inoperable in 21 patients and operable in 34 patients) who received IGPT between July 2013 and February 2017 were analyzed. The median patient age was 71 years (range: 48-88 years). IGPT with fiducial metallic marker matching was performed for suitable patients, and a respiratory gating method for motion management was used for all treatments. Peripherally located tumors were treated with 66 Gy relative biological effectiveness equivalents (Gy(RBE)) in 10 fractions (n = 49) and centrally located tumors were treated with 72.6 Gy(RBE) in 22 fractions (n = 6). Treatment associated toxicities were evaluated using Common Toxicity Criteria for Adverse Events (v.4.0). RESULTS: Median follow-up was 35 months (range: 12-54 months) for survivors. For all patients, the 3-year overall survival, progression-free survival, and local control rates were 87% (95% confidence interval: 73-94%), 74% (58-85%), and 96% (83-99%), respectively. Fiducial marker matching was used in 39 patients (71%). Grade 2 toxicities observed were radiation pneumonitis in 5 patients (9%), rib fracture in 2 (4%), and chest wall pain in 5 (9%). There were no grade 3 or higher acute or late toxicities. CONCLUSIONS: IGPT appears to be effective and well tolerated for all patients with stage I NSCLC. TRIAL REGISTRATION: Lung-001, 13-02-09 (9), registered 11 June 2013 and Lung-002, 13-02-10 (10), registered 11 June 2013.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nakajima K, Iwata H, Ogino H, et al. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer. Radiat Oncol. 2018. PMID: 30305125. doi:10.1186/s13014-018-1144-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。